A Randomized, Double-Blind, Placebo-Controlled Phase III Trial Of TSU-68 In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma.

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 09 Aug 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 Jul 2014 Trial terminated after interim analysis by an independent data monitoring committee found pre-determined standard related to the primary endpoint of overall survival was not met, according to a Taiho Pharmaceutical media release.
31 Jul 2014 Primary endpoint (Overall survival) has not been met, according to a Taiho Pharmaceutical media release.
31 Jul 2014 Status changed from active, no longer recruiting to discontinued, according to a Taiho Pharmaceutical media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com